Screening of calpain-3 autolytic activity in LGMD muscle: A functional map of CAPN3 gene mutations

M. Fanin, A. C. Nascimbeni, C. Angelini

Research output: Contribution to journalArticle

Abstract

Background: The diagnosis of calpainopathy is obtained by identifying calpain-3 protein deficiency or CAPN3 gene mutations. However, in many patients with limb girdle muscular dystrophy type 2A (LGMD2A), the calpain-3 protein quantity is normal because loss-of-function mutations cause its enzymatic inactivation. The identification of such patients is difficult unless a functional test suggests pursuing a search for mutations. Materials and methods: A functional in vitro assay, which was able to test calpain-3 autolytic function, was used to screen a large series of muscle biopsy specimens from patients with unclassified LGMD/hyperCKaemia who have previously shown normal calpain-3 protein quantity. Results: Of 148 muscle biopsy specimens tested, 17 samples (11%) had lost normal autolytic function. CAPN3 gene mutations were identified in 15 of 17 patients (88%), who account for about 20% of the total patients with LGMD2A diagnosed in our series. Conclusions: The loss of calpain-3 autolytic activity is highly predictive of primary calpainopathy, and the use of this test as part of calpainopathy diagnosis would improve the rate of disease defection markedly. This study provides the first evidence of the pathogenetic effect of specific CAPN3 gene mutations on the corresponding protein function in LGMD2A muscle and offers new insights into the structural-functional relationship of the gene and protein regions that are crucial for the autolytic activity of calpain-3.

Original languageEnglish
Pages (from-to)38-43
Number of pages6
JournalJournal of Medical Genetics
Volume44
Issue number1
DOIs
Publication statusPublished - Jan 2007

Fingerprint

Calpain
Muscles
Mutation
Genes
Proteins
Biopsy
Protein Deficiency
Limb-girdle muscular dystrophy type 2A

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Screening of calpain-3 autolytic activity in LGMD muscle : A functional map of CAPN3 gene mutations. / Fanin, M.; Nascimbeni, A. C.; Angelini, C.

In: Journal of Medical Genetics, Vol. 44, No. 1, 01.2007, p. 38-43.

Research output: Contribution to journalArticle

Fanin, M. ; Nascimbeni, A. C. ; Angelini, C. / Screening of calpain-3 autolytic activity in LGMD muscle : A functional map of CAPN3 gene mutations. In: Journal of Medical Genetics. 2007 ; Vol. 44, No. 1. pp. 38-43.
@article{5e557e5ac6c34e1a92eaa525081190be,
title = "Screening of calpain-3 autolytic activity in LGMD muscle: A functional map of CAPN3 gene mutations",
abstract = "Background: The diagnosis of calpainopathy is obtained by identifying calpain-3 protein deficiency or CAPN3 gene mutations. However, in many patients with limb girdle muscular dystrophy type 2A (LGMD2A), the calpain-3 protein quantity is normal because loss-of-function mutations cause its enzymatic inactivation. The identification of such patients is difficult unless a functional test suggests pursuing a search for mutations. Materials and methods: A functional in vitro assay, which was able to test calpain-3 autolytic function, was used to screen a large series of muscle biopsy specimens from patients with unclassified LGMD/hyperCKaemia who have previously shown normal calpain-3 protein quantity. Results: Of 148 muscle biopsy specimens tested, 17 samples (11{\%}) had lost normal autolytic function. CAPN3 gene mutations were identified in 15 of 17 patients (88{\%}), who account for about 20{\%} of the total patients with LGMD2A diagnosed in our series. Conclusions: The loss of calpain-3 autolytic activity is highly predictive of primary calpainopathy, and the use of this test as part of calpainopathy diagnosis would improve the rate of disease defection markedly. This study provides the first evidence of the pathogenetic effect of specific CAPN3 gene mutations on the corresponding protein function in LGMD2A muscle and offers new insights into the structural-functional relationship of the gene and protein regions that are crucial for the autolytic activity of calpain-3.",
author = "M. Fanin and Nascimbeni, {A. C.} and C. Angelini",
year = "2007",
month = "1",
doi = "10.1136/jmg.2006.044859",
language = "English",
volume = "44",
pages = "38--43",
journal = "Journal of Medical Genetics",
issn = "0022-2593",
publisher = "BMJ Publishing Group",
number = "1",

}

TY - JOUR

T1 - Screening of calpain-3 autolytic activity in LGMD muscle

T2 - A functional map of CAPN3 gene mutations

AU - Fanin, M.

AU - Nascimbeni, A. C.

AU - Angelini, C.

PY - 2007/1

Y1 - 2007/1

N2 - Background: The diagnosis of calpainopathy is obtained by identifying calpain-3 protein deficiency or CAPN3 gene mutations. However, in many patients with limb girdle muscular dystrophy type 2A (LGMD2A), the calpain-3 protein quantity is normal because loss-of-function mutations cause its enzymatic inactivation. The identification of such patients is difficult unless a functional test suggests pursuing a search for mutations. Materials and methods: A functional in vitro assay, which was able to test calpain-3 autolytic function, was used to screen a large series of muscle biopsy specimens from patients with unclassified LGMD/hyperCKaemia who have previously shown normal calpain-3 protein quantity. Results: Of 148 muscle biopsy specimens tested, 17 samples (11%) had lost normal autolytic function. CAPN3 gene mutations were identified in 15 of 17 patients (88%), who account for about 20% of the total patients with LGMD2A diagnosed in our series. Conclusions: The loss of calpain-3 autolytic activity is highly predictive of primary calpainopathy, and the use of this test as part of calpainopathy diagnosis would improve the rate of disease defection markedly. This study provides the first evidence of the pathogenetic effect of specific CAPN3 gene mutations on the corresponding protein function in LGMD2A muscle and offers new insights into the structural-functional relationship of the gene and protein regions that are crucial for the autolytic activity of calpain-3.

AB - Background: The diagnosis of calpainopathy is obtained by identifying calpain-3 protein deficiency or CAPN3 gene mutations. However, in many patients with limb girdle muscular dystrophy type 2A (LGMD2A), the calpain-3 protein quantity is normal because loss-of-function mutations cause its enzymatic inactivation. The identification of such patients is difficult unless a functional test suggests pursuing a search for mutations. Materials and methods: A functional in vitro assay, which was able to test calpain-3 autolytic function, was used to screen a large series of muscle biopsy specimens from patients with unclassified LGMD/hyperCKaemia who have previously shown normal calpain-3 protein quantity. Results: Of 148 muscle biopsy specimens tested, 17 samples (11%) had lost normal autolytic function. CAPN3 gene mutations were identified in 15 of 17 patients (88%), who account for about 20% of the total patients with LGMD2A diagnosed in our series. Conclusions: The loss of calpain-3 autolytic activity is highly predictive of primary calpainopathy, and the use of this test as part of calpainopathy diagnosis would improve the rate of disease defection markedly. This study provides the first evidence of the pathogenetic effect of specific CAPN3 gene mutations on the corresponding protein function in LGMD2A muscle and offers new insights into the structural-functional relationship of the gene and protein regions that are crucial for the autolytic activity of calpain-3.

UR - http://www.scopus.com/inward/record.url?scp=33846439375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846439375&partnerID=8YFLogxK

U2 - 10.1136/jmg.2006.044859

DO - 10.1136/jmg.2006.044859

M3 - Article

C2 - 16971480

AN - SCOPUS:33846439375

VL - 44

SP - 38

EP - 43

JO - Journal of Medical Genetics

JF - Journal of Medical Genetics

SN - 0022-2593

IS - 1

ER -